EA200702201A1 - Рофлумиласт для лечения лёгочной гипертензии - Google Patents

Рофлумиласт для лечения лёгочной гипертензии

Info

Publication number
EA200702201A1
EA200702201A1 EA200702201A EA200702201A EA200702201A1 EA 200702201 A1 EA200702201 A1 EA 200702201A1 EA 200702201 A EA200702201 A EA 200702201A EA 200702201 A EA200702201 A EA 200702201A EA 200702201 A1 EA200702201 A1 EA 200702201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
roflumilast
treatment
pulmonary hypertension
pharmaceutically acceptable
oxide
Prior art date
Application number
EA200702201A
Other languages
English (en)
Other versions
EA016037B1 (ru
Inventor
Рольф Бойме
Армин Хатцельманн
Дегенхард Маркс
Кристиан Шудт
Германн Тенор
Саадиа Эддаиби
Серж Адно
Original Assignee
Никомед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Никомед Гмбх filed Critical Никомед Гмбх
Publication of EA200702201A1 publication Critical patent/EA200702201A1/ru
Publication of EA016037B1 publication Critical patent/EA016037B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению рофлумиласта, фармацевтически приемлемой соли рофлумиласта, N-оксида рофлумиласта и фармацевтически приемлемой соли N-оксида рофлумиласта для лечения легочной гипертензии. Настоящее изобретение относится к применению рофлумиласта, фармацевтически приемлемой соли рофлумиласта, N-оксида рофлумиласта и фармацевтически приемлемой соли N-оксида рофлумиласта, в комбинации с ингибитором PDE5 или его фармацевтически приемлемой солью, для лечения легочной гипертензии.
EA200702201A 2005-04-19 2006-04-12 Рофлумиласт для лечения лёгочной гипертензии EA016037B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103147 2005-04-19
PCT/EP2006/061557 WO2006111495A1 (en) 2005-04-19 2006-04-12 Roflumilast for the treatment of pulmonary hypertension

Publications (2)

Publication Number Publication Date
EA200702201A1 true EA200702201A1 (ru) 2008-04-28
EA016037B1 EA016037B1 (ru) 2012-01-30

Family

ID=34939388

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702201A EA016037B1 (ru) 2005-04-19 2006-04-12 Рофлумиласт для лечения лёгочной гипертензии

Country Status (24)

Country Link
US (1) US8648100B2 (ru)
EP (2) EP2366393B1 (ru)
JP (2) JP2008536888A (ru)
KR (1) KR101358479B1 (ru)
CN (2) CN101163476A (ru)
AU (1) AU2006237300B2 (ru)
BR (1) BRPI0610498A2 (ru)
CA (1) CA2604295C (ru)
CY (1) CY1114468T1 (ru)
DK (1) DK2366393T3 (ru)
EA (1) EA016037B1 (ru)
ES (1) ES2433661T3 (ru)
HR (1) HRP20130982T1 (ru)
IL (2) IL186538A0 (ru)
ME (1) ME01609B (ru)
MX (1) MX2007012711A (ru)
NO (1) NO20075662L (ru)
NZ (1) NZ561746A (ru)
PL (1) PL2366393T3 (ru)
PT (1) PT2366393E (ru)
RS (1) RS52944B (ru)
SI (1) SI2366393T1 (ru)
WO (1) WO2006111495A1 (ru)
ZA (1) ZA200707930B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649302B2 (en) 2013-01-28 2017-05-16 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2009115235A1 (en) * 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107038965A (zh) * 2017-05-05 2017-08-11 深圳浩翔光电技术有限公司 Led显示装置、成型模组、及其生产工艺
KR20190005708A (ko) 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
CN115969847A (zh) * 2023-02-03 2023-04-18 华中科技大学 罗氟司特在制备治疗心力衰竭的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB343664A (en) 1929-12-27 1931-02-26 William Duncan Grant Subaquatic rock drilling devices
GB357903A (en) 1931-01-05 1931-10-01 Oskar Rosenfelder Improvements in catamenial appliances and infants' diapers
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
EP0706513B1 (de) 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU6823098A (en) * 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
NZ338075A (en) 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
CA2329077C (en) 1998-04-20 2007-09-18 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
WO2000056719A1 (en) 1999-03-22 2000-09-28 Bristol-Myers Squibb Company FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PL364910A1 (en) 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
US20020174207A1 (en) * 2001-02-28 2002-11-21 Abdella Battou Self-healing hierarchical network management system, and methods and apparatus therefor
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1441730B1 (en) * 2001-11-05 2006-08-09 Merck Patent GmbH Hydrazono-malonitriles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP2005532321A (ja) * 2002-05-16 2005-10-27 ファルマシア コーポレーション 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1634606A1 (en) * 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
WO2004105751A1 (en) * 2003-05-28 2004-12-09 Glaxo Group Limited Traitement of cardiovascular pathology
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
RU2006108864A (ru) 2003-08-22 2007-09-27 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
MXPA06012279A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649302B2 (en) 2013-01-28 2017-05-16 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide
US11103488B2 (en) 2013-01-28 2021-08-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide

Also Published As

Publication number Publication date
MX2007012711A (es) 2008-01-11
EP2366393A2 (en) 2011-09-21
ME01609B (me) 2014-09-20
IL186538A0 (en) 2008-06-05
PT2366393E (pt) 2013-10-04
BRPI0610498A2 (pt) 2010-06-22
CN101163476A (zh) 2008-04-16
SI2366393T1 (sl) 2013-12-31
ES2433661T3 (es) 2013-12-12
NZ561746A (en) 2011-09-30
US20090215836A1 (en) 2009-08-27
EA016037B1 (ru) 2012-01-30
CA2604295A1 (en) 2006-10-26
AU2006237300B2 (en) 2011-10-13
WO2006111495A1 (en) 2006-10-26
KR101358479B1 (ko) 2014-02-06
JP2013237683A (ja) 2013-11-28
CA2604295C (en) 2014-10-07
EP2366393B1 (en) 2013-08-07
NO20075662L (no) 2007-11-07
CN102614176A (zh) 2012-08-01
ZA200707930B (en) 2008-05-28
AU2006237300A1 (en) 2006-10-26
CY1114468T1 (el) 2017-01-25
JP2008536888A (ja) 2008-09-11
HRP20130982T1 (hr) 2013-11-22
KR20080002950A (ko) 2008-01-04
IL218745A0 (en) 2012-05-31
RS52944B (en) 2014-02-28
US8648100B2 (en) 2014-02-11
EP2366393A3 (en) 2011-09-28
EP1874309A1 (en) 2008-01-09
PL2366393T3 (pl) 2014-01-31
DK2366393T3 (da) 2013-10-21

Similar Documents

Publication Publication Date Title
EA201070786A1 (ru) Бензофуропиримидиноны
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
LTPA2013018I1 (lt) 4-oksochinolino junginiai ir jų, kaip živ inregrazės inhibitorių, panaudojimas
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
ATE447568T1 (de) Neue pyrinderivate
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EA201000145A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
NL1028761A1 (nl) Dipeptidylpeptidase-IV remmers.
EA200870409A1 (ru) Антагонисты киназы pi3
TW200801006A (en) Fused bicyclic mTOR inhibitors
NO20064555L (no) HIV-integraseinhibitorer.
MX2009006505A (es) Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para usarlas en el tratamiento de la presbiopia.
EA200702201A1 (ru) Рофлумиласт для лечения лёгочной гипертензии
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
NO20092146L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
EP1850852A4 (en) USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
DE602004012448D1 (de) Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus
DK1933840T3 (da) Anvendelse af delmopinol i behandlingen af acne
ATE435865T1 (de) Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU